| SEC Form 4 |  |
|------------|--|
|------------|--|

Instruction 1(b).

## FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

Ir

| STATEMENT OF CHANGES IN BENI                      | OMB Number:              | 3235-0287             |        |  |  |
|---|--------------------------|-----------------------|--------|--|--|
|   | Estimated average burden |                       |        |  |  |
| Filed pursuant to Section 16(a) of the Securities | hours per response:      | 0.5                   |        |  |  |
| or Section 30(h) of the Investment Comp           |                          |                       |        |  |  |
| 2. Issuer Name and Ticker or Trading Sy           | 5. Relationship of R     | eporting Person(s) to | Issuer |  |  |

| 1. Name and Address of Reporting Person <sup>*</sup><br>Stewart Murray |   |                | 2. Issuer Name <b>and</b> Ticker or Trading Symbol<br>X4 Pharmaceuticals, Inc [XFOR]   | 5. Relationship of Reporting Person(s) to Issuer<br>(Check all applicable) |                                    |                       |  |  |  |  |
|--|---|----------------|--|--|------------------------------------|-----------------------|--|--|--|--|
| <u>Stewart Mit</u>   | <u>iiiay</u>  |                |  | X  | Director                           | 10% Owner             |  |  |  |  |
| (Last)   | (Last) (First) (Middle)<br>C/O X4 PHARMACEUTICALS, INC. |                | 3. Date of Earliest Transaction (Month/Day/Year)<br>08/09/2023   | x  | Officer (give title<br>below)      | Other (specify below) |  |  |  |  |
| C/O X4 PHA   |   |                | 00/05/2025   |  | Interim Chief Me                   | dical Officer         |  |  |  |  |
| 61 NORTH BEACON STREET, 4TH FLOOR                                      |   | EET, 4TH FLOOR | 4. If Amendment, Date of Original Filed (Month/Day/Year)   | 6. Individual or Joint/Group Filing (Check Appli<br>Line)                  |                                    |                       |  |  |  |  |
| (Street)   |   |                | -  | X  | Form filed by One Reporting Person |                       |  |  |  |  |
| BOSTON   | MA  | 02134          |  |  | Form filed by More the Person      | nan One Reporting     |  |  |  |  |
| (City)   | (State)   | (Zip)          | Rule 10b5-1(c) Transaction Indication  | •  |                                    |                       |  |  |  |  |
|  |   |                | Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10. |  |                                    |                       |  |  |  |  |

## Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

| 1. Title of Security (Instr. 3) | 2. Transaction<br>Date<br>(Month/Day/Year) | 2A. Deemed<br>Execution Date,<br>if any<br>(Month/Day/Year) |                         |   | 4. Securities A<br>Disposed Of ( |               |                       |                                    | 6. Ownership<br>Form: Direct<br>(D) or Indirect<br>(I) (Instr. 4) | 7. Nature<br>of Indirect<br>Beneficial<br>Ownership |
|---------------------------------|--|---|-------------------------|---|----------------------------------|---------------|-----------------------|------------------------------------|---|---|
|                                 |  |   | Code                    | v | Amount                           | (A) or<br>(D) | Price                 | Transaction(s)<br>(Instr. 3 and 4) |   | (Instr. 4)  |
| Common Stock                    | 08/09/2023                                 |   | A                       |   | 269,893(1)                       | A             | \$0                   | 276,560                            | D   |   |
| Common Stock                    | 08/10/2023                                 |   | <b>S</b> <sup>(2)</sup> |   | 130,056                          | D             | \$1.06 <sup>(3)</sup> | 146,504                            | D   |   |

## Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

(e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of<br>Derivative<br>Security<br>(Instr. 3) | 2.<br>Conversion<br>or Exercise<br>Price of<br>Derivative<br>Security | 3. Transaction<br>Date<br>(Month/Day/Year) | 3A. Deemed<br>Execution Date,<br>if any<br>(Month/Day/Year) | 4.<br>Transa<br>Code (<br>8) |   |  |  | ate | 7. Titl<br>Amou<br>Secur<br>Unde<br>Deriv<br>Secur<br>3 and | unt of<br>rities<br>rlying<br>ative<br>rity (Instr. | Derivative<br>Security<br>(Instr. 5)   | 9. Number of<br>derivative<br>Securities<br>Beneficially<br>Owned<br>Following<br>Reported<br>Transaction(s)<br>(Instr. 4) | Ownership<br>Form:<br>Direct (D) | 11. Nature<br>of Indirect<br>Beneficial<br>Ownership<br>(Instr. 4) |  |
|---|---|--|---|------------------------------|---|--|--|-----|---|---|--|--|----------------------------------|--|--|
|   |   |  |   | Code                         | v |  |  |     | Expiration<br>Date  | Title   | Amount<br>or<br>Number<br>of<br>Shares |  |                                  |  |  |

Explanation of Responses:

1. Represents shares of common stock acquired upon acceleration of the vesting of a performance-based restricted stock unit grant.

2. Represents nondiscretionary sale of shares required to be sold by the Reporting Person pursuant to sell to cover transactions to satisfy tax withholding obligations in connection with the settlement of restricted stock units.

3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$1.02 to \$1.10 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

**Remarks:** 

/s/ Adam S. Mostafa, attorney-08/11/2023 in-fact

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.